- Stocks
- Pharma & Healthcare
- Themis Medicare
Themis Medicare share price
NSE: THEMISMEDPharma & HealthcareDrug Manufacturers - Specialty & Generic
Themis Medicare at a glance
Themis Medicare (NSE: THEMISMED) closed at ₹96.57 on 21 Oct 2026. With a market capitalisation of ₹944 Cr, it ranks 1396th by market cap among the 3,928 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 7.5% in FY25. Its 52-week range is ₹64.95 (30 Mar 2026) to ₹140.60 (7 Sep 2026); the last close is 31.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹77 Cr (+6.7% year on year) and net profit ₹2 Cr, on a consolidated basis. Promoters held 67.11% of the company as of 30 Jun 2026; 43.39% of promoter shares were pledged.
Key numbers
- Market cap
- ₹944 CrRank 1396 on NSE
- Price to book
- 4.21×FY25
- EPS (TTM)
- ₹0.13to Q4 FY26
- ROE
- 7.5%FY25
- ROCE
- 12.5%FY25
- Debt to equity
- 0.26FY25
- Net profit margin
- 5.9%FY25
- Book value / share
- ₹34.80FY25
- Dividend payout
- 19.2%FY25
- 52-week high
- ₹140.607 Sep 2026
- 52-week low
- ₹64.9530 Mar 2026
Returns to —
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Themis Medicare quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹123 Cr | ₹117 Cr | ₹94 Cr | ₹72 Cr | ₹98 Cr | ₹78 Cr | ₹90 Cr | ₹77 Cr |
| Revenue YoY | +27.3% | +11.7% | +13.7% | −26.7% | −20.7% | −33.3% | −3.9% | +6.7% |
| Net profit | ₹19 Cr | ₹10 Cr | ₹3 Cr | −₹8 Cr | −₹14 Cr | −₹5 Cr | ₹5 Cr | ₹2 Cr |
| Net profit YoY | +49.1% | +39.0% | +54.0% | −352.4% | −175.3% | −154.3% | +48.7% | — |
| Net margin | 15.2% | 8.4% | 3.3% | −10.8% | −14.4% | −6.9% | 5.1% | 2.6% |
| EPS | ₹2.68 | ₹1.55 | ₹0.06 | −₹1.05 | −₹1.54 | −₹0.39 | ₹1.10 | ₹0.96 |
Themis Medicare financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹231 Cr | ₹395 Cr | ₹354 Cr | ₹382 Cr | ₹406 Cr | — |
| Operating profit | ₹32 Cr | ₹84 Cr | ₹59 Cr | ₹35 Cr | ₹34 Cr | — |
| Net profit | ₹26 Cr | ₹62 Cr | ₹43 Cr | ₹25 Cr | ₹24 Cr | — |
| EPS (₹) | ₹39.00 | ₹79.00 | ₹62.00 | ₹5.00 | ₹3.00 | — |
| Cash from operations | ₹57 Cr | ₹34 Cr | ₹16 Cr | ₹22 Cr | ₹35 Cr | — |
| Total debt | ₹22 Cr | ₹24 Cr | ₹28 Cr | ₹27 Cr | ₹19 Cr | ₹22 Cr |
| Shareholders' equity | ₹219 Cr | ₹287 Cr | ₹339 Cr | ₹378 Cr | ₹403 Cr | ₹399 Cr |
Themis Medicare shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 67.15% | 67.15% | 67.11% | 67.11% | 67.11% |
| Foreign institutions | 0.10% | 0.06% | 0.05% | 0.11% | 0.01% |
| Domestic institutions | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Non-institutions | 32.74% | 32.78% | 32.83% | 32.78% | 32.87% |
| Promoter shares pledged | 2.43% | 2.43% | 2.43% | 2.43% | 43.39% |
Themis Medicare vs peers
The listed Pharma & Healthcare companies nearest to Themis Medicare by market capitalisation.
Ask anything about Themis Medicare
Pivot answers on the live chart with evidence you can check, and tests strategies against THEMISMED's own history. Try: “Why has THEMISMED moved over the last three months?” · “Backtest a 50-day moving-average crossover on THEMISMED over five years” · “Compare THEMISMED with GKSL on margins and valuation”
Frequently asked questions about Themis Medicare
What is the share price of Themis Medicare today?
Themis Medicare (NSE: THEMISMED) last closed at ₹96.57 on 21 Oct 2026. Its 52-week high is ₹140.60 and its 52-week low is ₹64.95.
What is the market cap of Themis Medicare?
Themis Medicare's market capitalisation is ₹944 Cr (₹944 Cr) at the — close, ranking 1396th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Themis Medicare?
Return on equity was 7.5% in FY25 and return on capital employed was 12.5% in FY25 (standalone figures).
Is Themis Medicare a debt-free company?
No. Themis Medicare's debt-to-equity ratio was 0.26 in FY25, with total debt of ₹22 Cr.
What were Themis Medicare's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Themis Medicare reported revenue of ₹77 Cr, +6.7% year on year, and net profit of ₹2 Cr.
What is the shareholding pattern of Themis Medicare?
As of 30 Jun 2026: promoters 67.11%, foreign institutions 0.01%, domestic institutions 0.01%, non-institutions 32.87%. 43.39% of promoter shares were pledged.
Who are Themis Medicare's competitors?
The listed Pharma & Healthcare companies closest to Themis Medicare by market cap are Gujarat Kidney And Super Speciality, Kopran, Wanbury, Shree Ganesh Re, Sigachi Industries and Anlon Healthcare.
Is Themis Medicare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Themis Medicare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on THEMISMED against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026. Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 3,928 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with T · all NSE stocks · this page as text